Medical imaging software developer Median Technologies has entered a collaboration with Japanese CRO pioneer CMIC to support oncology drug development in East Asia.
CMIC will be able to access Median’s imaging technologies, services and imaging expertise, while Median expands its relationship with clinical trial sponsors in Asia.
Imaging contract research services that Median offers to clinical trials cover all phases and span across the entire study process, from imaging protocol design, site training, image data collection and management, to independent radiological review and final reporting. It recently launched the iSee platform, which enables rapid analysis and better management of medical images in clinical trials.
Oncology is the key area of focus at Median. Last April, the company reached a strategic alliance with inVentiv Health (now Syneos Health) focused specifically on oncology studies. InVentiv has worked on more than 78% of oncology products approved by the FDA and 84% of oncology drugs approved by the EMA in the recent five years, according to the companies’ joint statement at the time.
Median has also been accelerating its expansion in Asia, having recently opened a subsidiary in Shanghai and named leaders for its businesses in China and Japan. “Our CMIC collaboration strengthens our efforts and extends our footprint for our clinical trial business in the fast-growing Asian market,” said Nicholas Campbell, Median’s CCO.
CMIC became the first Japanese CRO when it opened shop in 1992, and it’s now a full-service CRO with capabilities in drug R&D, manufacturing, sales and marketing. For the fiscal year ended Sep. 30, 2017, the company’s CRO business reported sales growth of 7.8% to reach 34.2 billion Japanese yen ($320 million).